Top Trending Tickers On StockTwits For February 6
Here's a look at the top tickers trending on StockTwits.com
Twitter: First ever quarterly report disappoints investors
Last night, Twitter (NYSE: TWTR) reported its first ever quarterly report. The company announced that its fourth quarter EPS of $0.02 beat the consensus estimate of -$0.01. Revenue of $243 million beat the consensus estimate of $216.86 million.
Twitter reported that it saw a decline in Timeline views on a quarterly basis and slowing monthly average user growth in the fourth quarter. The company ended the quarter with 20 percent as many monthly average users as Facebook.
The company's CEO Dick Costolo admitted that that the platform needs to improve and become easier for new users to grasp and that the company is still in the early stages of monetization and e-commerce opportunities.
Shares were trading lower by 21 percent.
Green Mountain Coffee Roasters: Company announces partnership with Coca-Cola
As part of the agreement, Coca-Cola will purchase a ten percent stake in Green Mountain and the two will collaborate on the Keurig cold platform. Green Mountain will be Coke's exclusive partner for “the production and sale of The Coca-Cola Company-branded single-serve, pod based cold beverages.”
Green Mountain also reported its first quarter results. The company announced an EPS of $0.96, beating the consensus estimate of $0.90. Revenue of $1.38 billion missed the consensus estimate of $1.4 billion.
Green Mountain expects its second quarter EPS to be $0.93 to $0.98, below the consensus estimate of $1.02. Full year 2014 EPS is expected to be $3.75 to $3.85 with a consensus of $3.82.
This morning, analyst at KeyBanc raised their target on Green Mountain to $150.
shares of Green Mountain were trading higher by 40.58 percent, while Coca-Cola traded higher by 1.57 percent.
General Motors: Earnings miss
This morning, General Motors (NYSE: GM) reported its fourth quarter earnings. The company announced an EPS of $0.67, missing the consensus estimate of $0.87. Revenue of $40.5 billion missed the consensus estimate of $40.11 billion.
General Motors said that it's “2013 calendar-year net income attributable to common stockholders of $3.8 billion, or $2.38 per fully diluted share, down from $4.9 billion, or $2.92 per fully diluted share in 2012. Operating performance improved during the year, but was more than offset by a net loss from special items and incremental tax expense.”
General Motors said that it is now in “execution” mode and that its “sole focus will be on delivering results on a global basis.”
Shares were trading lower by 4.09 percent in the pre-market session.
Dunkin' Brands: Solid quarterly results
This morning, Dunkin' Brands (NASDAQ: DNKN) reported its fourth quarter results. The company announced an EPS of $0.43, beating the consensus estimate of $0.40. Revenue of $183.17 million beat the consensus estimate of $178.5 million.
During the quarter, Dunkin' Brands saw its comparable store sales growth of 3.5 percent and has added 309 net new restaurants worldwide, 149 of which was in the U.S.
"Our fourth quarter was strong, capping off a great year in which we set records and achieved major milestones for both Dunkin' Donuts and Baskin-Robbins," said Nigel Travis, Chairman and Chief Executive Officer, Dunkin' Brands in a press release. "The Dunkin' Donuts U.S. annual net development growth rate exceeded five percent, and Baskin-Robbins had positive net development for the first time since 2006. Dunkin' Donuts U.S. had 3.4 percent comparable store sales growth in 2013.”
Shares were trading higher by 2.14 percent in the pre-market session.
Teva Pharmaceutical: Profit boosted by generics
This morning, Teva Pharmaceutical (NASDAQ: TEVA) reported its fourth quarter results. The company announced an EPS of $1.42, beating the consensus estimate of $1.40. Revenue of $5.45 billion beat the consensus estimate of $5.02 billion.
Teva's net profit for the quarter rose to $380 billion from last quarter's $320 million. The company noted a higher sale of generic medicines in the U.S. Total generic sales rose one percent to $2.7 billion, specialty medicines rose five percent to $2.2 billion and Copaxone rose eight percent to $1.1 billion.
“Teva is reporting today strong results for the fourth quarter of 2013, bringing to close a year largely in-line with our expectations. During 2013, we had several key product launches, driven by a strong pipeline, which will continue to bear notable results in 2014, starting with the launch of COPAXONE 40mg/mL,” said Eyal Desheh, Acting President and CEO of Teva.
Shares were trading higher by 1.82 percent in the pre-market session.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.